Meta-analysis and GWAS analysis indicate that the GCKR rs1260326 has possibly impaired the hepatic lipid metabolism and significantly contributes to the development of obesity and obesity-associated metabolic disorder including NAFLD and T2DM. Here, GCKR is linked to metabolic disease.